title: Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected men.
abstract: In the context of HIV, the initiation of effective antiretroviral therapy (ART) has been found to increase the risk of dyslipidemia in HIV-infected individuals, and dyslipidemia has been found to be a risk factor for kidney disease in the general population. Therefore, we examined changes in lipid profiles in HIV-infected men following ART initiation and the association with future kidney dysfunction. HIV-infected men from the Multicenter AIDS Cohort Study initiating ART between December 31, 1995 and September 30, 2011 with measured lipid and serum creatinine values pre-ART and post-ART were selected. The associations between changes in total cholesterol or high-density lipoprotein following ART initiation and the estimated change in glomerular filtration rate (eGFR) over time were assessed using piecewise linear mixed effects models. There were 365 HIV-infected men who contributed to the analysis. In the adjusted models, at 3 years post-ART, those with changes in total cholesterol >50 mg/dl had an average decrease in eGFR of 2.6 ml/min/1.73 m(2) per year (p<0.001) and at 5 years post-ART, the average decrease was 2.4 ml/min/1.73 m(2) per year (p=0.008). This decline contrasted with the estimates for those with changes in total cholesterol ≤ 50 mg/dl: 1.4 ml/min/1.73 m(2) decrease per year (p<0.001) and 0.1 ml/min/1.73 m(2) decrease per year (p=0.594) for the same time periods, respectively. Large decreases in high-density lipoprotein (a decline of greater than 5 mg/dl) were not associated with declines in eGFR. These results indicate that large ART-related increases in total cholesterol may be a risk factor for kidney function decline in HIV-infected men. Should these results be generalizable to the broader HIV population, monitoring cholesterol changes following the initiation of ART may be important in identifying HIV-infected persons at risk for kidney disease.
authors.affiliation: 1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland.
authors.forename: Alison G
authors.initials: AG
authors.lastname: Abraham
authors.forename: Xiuhong
authors.initials: X
authors.lastname: Li
authors.forename: Lisa P
authors.initials: LP
authors.lastname: Jacobson
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Estrella
authors.forename: Rhobert W
authors.initials: RW
authors.lastname: Evans
authors.forename: Mallory D
authors.initials: MD
authors.lastname: Witt
authors.forename: John
authors.initials: J
authors.lastname: Phair
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D050171:Dyslipidemias / Q000139:chemically induced* / Q000150:complications*; D005919:Glomerular Filtration Rate; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D007677:Kidney Function Tests; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry; D018570:Risk Assessment
chemical_list: D008055:Lipids; D003404:Creatinine